Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632239 | 0.94 | GAA (0.63) | GAANPC1RAB9ACDK1CYP1A2 | |
| SCHEMBL10733156 | 0.86 | GAA (0.52) | GAATSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3777329 | 0.81 | GAA (0.61) | GAACDK1CYP1A2TP53GLA | |
| SCHEMBL10730763 | 0.79 | GAA (0.58) | GAATSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11121612 | 0.79 | TSHR (0.69) | GAATSHRSMN1; SMN2TP53GLA | |
| SCHEMBL10877469 | 0.78 | GAA (0.54) | GAATSHRSMN1; SMN2CDK1CYP1A2 | |
| SCHEMBL10987885 | 0.78 | GAA (0.48) | GAATSHRSMN1; SMN2CDK1TP53 | |
| SCHEMBL2622461 | 0.77 | GAA (0.51) | GAASMN1; SMN2CDK1CYP1A2TP53 | |
| SCHEMBL11560856 | 0.77 | GAA (0.55) | GAATSHRSMN1; SMN2CDK1TP53 | |
| SCHEMBL10885268 | 0.76 | GAA (0.54) | GAATSHRSMN1; SMN2NPC1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | GAA 166/4885TSHR 4401/4885SMN1; SMN2 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.